Loading...
Intec Pharma Ltd
NTEC•NASDAQ
Healthcare
Biotechnology
$9.63
$-1.37(-12.45%)

Financial performance has remained strong, with revenue growing from $0.00 in Q2 2020 to $0.00 in Q1 2021. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$4.18M in Q1 2021, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$3.65M. Net income dropped to -$4.23M, keeping EPS at -$3.83. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan